Loading stock…

Amrize AG (AMRZ) Stock Verdict & Ratings | Investment Bastion

02Growth

Is it actually growing, and how fast?

AMRZAmrize

Revenue FY25$11.7B

GROWTH RATING↗

WEAK32 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+3%4

Revenue, next 1Y+6%5

Revenue, next 3Y, CAGR+5%4

Revenue, next 5Y, CAGR+4%3

EARNINGS FORECAST▾SCORE

EPS growth, FY26E-1%3

EPS growth, FY27E+12%7

EPS growth, FY28E+12%7

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow faster than sales (EPS about 12%/yr vs revenue 5%/yr), so margins should widen.

WATCH

Revenue is set to grow 5%/yr over the next 3 years, a little behind the market.4/10

Revenue grew 3%/yr over the last 3 years and is set to keep growing around 5%/yr.

WEAKNESSES

Growth is the weak spot here, trailing 68% of companies worldwide.

Over five years revenue is set to grow 4%/yr, behind 70% of companies worldwide.3/10

BOTTOM LINE

Steady Grower

Growth is a weak point here. The one thing to watch: the five-year outlook is thin.

03Price Momentum

Is the market behind it right now?

Cumulative Return

No data

MOMENTUM RATING↗

VERY WEAK2 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-15%1

3-month return-27%1

YTD return-30%1

MID & LONG-TERM▾SCORE

% of 52-week high57%2

1-year return-20%2

3-year return-27%1

5-year return-27%2

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-27% over three years and -27% over five), behind 80% of the market.

It's down 20% over the past year, now 43% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-15%), over three months (-27%) and so far this year (-30%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Amrize AG. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

AMRZAmrize

Revenue FY25$11.7B

GROWTH RATING↗

WEAK32 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+3%4

Revenue, next 1Y+6%5

Revenue, next 3Y, CAGR+5%4

Revenue, next 5Y, CAGR+4%3

EARNINGS FORECAST▾SCORE

EPS growth, FY26E-1%3

EPS growth, FY27E+12%7

EPS growth, FY28E+12%7

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow faster than sales (EPS about 12%/yr vs revenue 5%/yr), so margins should widen.

WATCH

Revenue is set to grow 5%/yr over the next 3 years, a little behind the market.4/10

Revenue grew 3%/yr over the last 3 years and is set to keep growing around 5%/yr.

WEAKNESSES

Growth is the weak spot here, trailing 68% of companies worldwide.

Over five years revenue is set to grow 4%/yr, behind 70% of companies worldwide.3/10

BOTTOM LINE

Steady Grower

Growth is a weak point here. The one thing to watch: the five-year outlook is thin.

03Price Momentum

Is the market behind it right now?

Cumulative Return

No data

MOMENTUM RATING↗

VERY WEAK2 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-15%1

3-month return-27%1

YTD return-30%1

MID & LONG-TERM▾SCORE

% of 52-week high57%2

1-year return-20%2

3-year return-27%1

5-year return-27%2

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-27% over three years and -27% over five), behind 80% of the market.

It's down 20% over the past year, now 43% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-15%), over three months (-27%) and so far this year (-30%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Amrize AG. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Amrize AG

01Key Ratings

02Growth

03Price Momentum

04Value

Stop guessing on Amrize AG. Get the full investment case.

Premium

02Growth

03Price Momentum

04Value

Stop guessing on Amrize AG. Get the full investment case.

Premium